CLINICAL STUDY

Relationship between inhibin A and B, estradiol and follicle growth dynamics during ovarian stimulation in normo-ovulatory women

Femke P Hohmann¹, Joop S E Laven¹, Frank H de Jong² and Bart C J M Fauser¹,³

¹Division of Reproductive Medicine, Department of Obstetrics and Gynecology, ²Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands and ³Department of Reproductive Medicine, University Medical Center, Utrecht, The Netherlands

(Correspondence should be addressed to Joop S E Laven; Email: j.laven@erasmusmc.nl)

Abstract

Objective: To investigate the relationship between serum concentrations of inhibin A, inhibin B and estradiol (E₂) and the number of developing follicles during the administration of exogenous follicle-stimulating hormone (FSH) in various regimens in normo-ovulatory volunteers and to evaluate if inhibins act as suitable markers for the number of developing follicles during ovarian stimulation.

Design and methods: Serial hormone determinations and assessment of follicle numbers were carried out during unstimulated cycles and during various interventions with exogenous FSH. Subjects were randomized for FSH administration into the following groups: a single high dose (375 IU) during the early follicular phase (group A), 5 consecutive low doses (75 IU/day) starting in the mid follicular phase (group B) or daily low doses (75 IU/day) during the early to late follicular phase (starting on cycle days 3, 5 or 7; groups C, D and E respectively).

Results: Extending the FSH window increases the number of small antral follicles and hence inhibin B serum concentrations. If such an intervention results in multi-follicular growth, mid follicular phase inhibin B \((P = 0.001)\) as well as late follicular phase inhibin B and inhibin A levels are significantly \((P < 0.05\) and \(P < 0.01\) respectively) increased compared with mono-follicular cycles or the natural cycle. Although mid follicular inhibin B levels correlated well with the number of small antral \((P < 0.05)\) and pre-ovulatory \((P < 0.001)\) follicles in the late follicular phase, mid follicular inhibin A and estradiol serum concentrations only correlated with the number of pre-ovulatory follicles \((P < 0.001\) and \(P < 0.01\) respectively).

Conclusions: The present data extend our understanding of the relationship between follicle dynamics, serum inhibins and FSH during ovarian hyperstimulation. However, although mid follicular inhibin B does correlate with the number of developing follicles, it does not facilitate the identification of women at risk for multiple follicle development.

European Journal of Endocrinology 152 395–401

Introduction

Inhibins are principally produced in the ovary by granulosa cells and selectively inhibit follicle-stimulating hormone (FSH) secretion by the pituitary (1). Inhibins are dimeric glycoproteins produced by the gonads, consisting of an \(\alpha\) subunit linked through disulfide binding with either a \(\beta_A\) or \(\beta_B\) subunit. The resulting \(\alpha\beta_A\) heterodimer is referred to as inhibin A, whereas the \(\alpha\beta_B\) protein constitutes inhibin B (2). Inhibin A seems to be the predominant form produced during the late follicular and luteal phases of the normal menstrual cycle, whereas inhibin B is the predominant form during the early and mid follicular phases of the cycle (2, 3).

Recent studies in normo-ovulatory women have shown convincingly that inhibin B is predominantly secreted by granulosa cells of pre-antral and small antral follicles and hence its concentration increases during the luteo–follicular transition (4). Inhibin B levels are highest during the mid follicular phase and decline during the late follicular phase (5, 6). A transient rise in inhibin B levels coincided with the mid-cyclic luteinizing hormone (LH) and FSH surge. Thereafter, inhibin B levels decline further to a nadir in the mid luteal phase (5, 7). Declining inhibin A levels during the late luteal phase seem to be the predominant regulator of rising FSH serum levels during the luteo–follicular transition and hence contribute to the dynamic changes within a menstrual cycle (8–11). In contrast, high inhibin B concentrations during the early follicular phase are responsible for the decline in FSH serum levels closing the FSH window and assuring single dominant follicle selection (12). This specific
differential pattern of inhibin A and inhibin B secretion is established during early puberty and remains constant throughout reproductive life (13).

Since the size of the cohort of recruited follicles appears to be related to the size of the primordial follicle pool (14), inhibin B may constitute a suitable marker of ovarian ageing (15, 16). Moreover, inhibin B serum levels have been suggested to predict poor response to ovarian hyperstimulation in in vitro fertilization (IVF) patients (17). Unfortunately, more detailed analyses concluded that early follicular phase inhibin B serum levels are only of limited value in predicting response during ovarian hyperstimulation (18–21). Dynamic inhibin B testing with FSH stimulation (22, 23) or gonadotropin releasing hormone (GnRH) agonist administration (24) appears to correlate better with ovarian response. A good correlation was also observed between inhibin B concentrations during ovarian hyperstimulation and the number of oocytes retrieved (25, 26).

However, most, if not all, of the aforementioned studies used GnRH agonist to suppress endogenous gonadotropins and consequently baseline inhibin B levels are decreased (27). Hence, results from these studies might not be readily applicable to stimulation protocols used for ovulation induction or minimal ovarian hyperstimulation in conjunction with intrauterine insemination during which GnRH analogs are not usually applied. The current study was designed to study the relationship between serum concentrations of inhibin A and inhibin B and the number of developing follicles during various ovarian hyperstimulation protocols without previous down regulation using a GnRH agonist.

Materials and methods

Subjects

This study was approved by the local Ethics Review Committee. A total group of 63 healthy volunteers was selected from responders to advertisements in local newspapers and interviews on the local radio and television. Written informed consent was obtained from each participant, and all subjects were paid for participation, as previously published (28, 29).

Inclusion criteria were: (i) a history of regular menstrual cycles (cycle length 25–32 days); (ii) age range of 19 to 35 years; (iii) body mass index (BMI) 18–27 kg/m²; (iv) mid luteal progesterone concentrations (assessed 7 days prior to expected menses) of at least 18 nmol/l and (v) no previous use of medication or oral contraceptives at least 3 months prior to the study. Patients with a past history of any endocrine disease or infertility were excluded. All participants either used non-steroidal contraception (intrauterine devices, condoms or prior tubal ligation) or refrained from sexual intercourse during the study period.

Interventions

The first 23 subjects were studied during a natural cycle, followed by an intervention cycle (study 1, groups A and B). The remaining 40 volunteers were studied during a single intervention cycle (study 2, groups C, D, E) (28, 29).

The natural cycle was assessed by means of daily transvaginal ultrasound scans (TVS) and daily blood sampling starting on day 12 after the assessed LH surge in the pre study cycle and concluding on the day of ovulation as assessed by TVS. Normal ovulation was confirmed by assessment of elevated progesterone levels (>18 nmol/l) 6 or 7 days later (30). The LH surge in the pre study cycle was determined using a urinary LH self-test (Clear-plan One Step, Unipath Ltd., Bedford, Beds, UK) starting 10 days after the onset of the previous menses.

Study 1 (groups A and B) For the subjects who were followed during a natural cycle, a second series of daily TVS and blood sampling started at day 10 (LH + 10) after the LH surge in the control cycle. Women were randomly assigned to group A or B as published previously (28). All participants received exogenous urinary FSH (Metrodin-HP, Serono Benelux BV, The Hague, The Netherlands) from the same batch. Group A received a single dose of 375 IU urinary FSH s.c. at day LH + 14, effectively increasing the FSH concentrations above the presumed threshold without affecting the length of the FSH window (31). Group B received a similar total dose in 5 consecutive injections of 75 IU/day urinary FSH s.c. starting on day LH + 19, thereby preventing decremental serum FSH concentrations in the mid to late follicular phase and thus widening the FSH window. FSH was administered shortly after the daily blood withdrawal. Daily TVS as well as blood sampling were continued until the day of sonographically assessed ovulation. Normal ovulation was confirmed by assessment of elevated progesterone levels 7 days later.

Study 2 (groups C, D and E) The remaining 40 subjects were randomly assigned to groups C, D and E, as published previously (29). All these subjects received a daily fixed dose of 75 IU recombinant FSH (recFSH; Gonal-F, Serono Benelux BV) starting on day 3, 5 or 7 respectively, until the day of human chorionic gonadotrophin (hCG) administration. As soon as the largest follicle reached a diameter of 18 mm or more a single dose of 5000 IU hCG (Profasi, Serono Benelux BV) was administered i.m. at 2200 h to induce ovulation. TVS as well as blood sampling were performed on a two daily basis starting on cycle day 3 until the largest follicle reached a diameter of 15 mm or more. Thereafter, ultrasound scans and blood sampling were performed daily until sonographically assessed ovulation. Ovulation was
confirmed by blood sampling and TVS 8 days after hCG administration.

Sonographic imaging was performed using a 6.5 MHz transvaginal transducer (model EUB-415/420; Hitachi Medical Corporation, Tokyo, Japan). The ovaries were localized and scanned as described previously (32). Follicle diameter was calculated as the mean diameter (measured in two dimensions when < 9 mm and measured in three dimensions when > 9 mm), as published previously (30, 32). A dominant follicle was defined as a follicle with a diameter of 10 mm or more, whereas a pre-ovulatory follicle should measure 15 mm or more. This distinction is clinically important since not all follicles measuring 10 mm or more reach the pre-ovulatory stage. Sonographically assessed ovulation was defined as a decrease in size of >50% of the largest follicle (≥ 18 mm).

**Hormone assays**

Blood samples were obtained by venepuncture and processed within 2 h after withdrawal. Serum was stored at −20°C until assayed. Serum levels of LH and FSH were measured using luminescence based immunoassays (Immulite, Diagnostic Products Corp., Los Angeles, CA, USA) whereas serum estradiol (E2) levels were measured using coated tube radioimmunoassays provided by the same supplier. Standards used in the gonadotrophin assays were based on WHO 2nd IRP 78/549 and WHO 1st IRP 68/40 for FSH and LH respectively. Sensitivities of the assays were 0.1 U/l for FSH and LH, and 10 pmol/l for E2. Intra- and interassay coefficients of variation were less than 5% and 6% for LH, less than 5% and 7% for FSH and less than 5% and 7% for E2 respectively.

Dimeric inhibin A and B levels were assessed using an immuno-enzymometric assay obtained from Serotec (Oxford, Oxon, UK), as described previously (6). The detection limit of the assay, defined as the amount of inhibin equivalent to the signal of the blank + 3 s.d. of this signal, was 3.4 ng/l for both inhibin A and B. Intra- and interassay coefficients of variation were less than 8% and 15% for inhibin A and less than 8% and 14% for inhibin B respectively. All samples from one subject were run within the same assay.

**Data analysis**

The early follicular phase was defined as day LH+14 – day LH+18 for the natural cycle and for groups A and B (intervention study 1) and as cycle day (CD) 1 – CD 5 for groups C, D and E (intervention study 2). The mid and late follicular phases were defined as day LH+19 – day LH+23 and day LH+24 – day LH surge (natural cycle, groups A and B) and CD 6 – CD 10 and CD 11 – day hCG (groups C, D and E) respectively. Data are presented as means and s.d. if distributed normally or as median and ranges if distributed otherwise. The early, mid or late follicular phase value of a subject is chosen to be the mean value in each phase, in order to prevent overrating of individual subjects in the calculations. Student’s t-test statistics were performed on normally distributed data. Whenever a non-parametric distribution was found, groups were compared using the Mann-Whitney U-test. Comparisons of outcome measures between more than 2 groups were performed using the Kruskal-Wallis H-test for continuous data and using the χ² test for binary variables. Comparisons of data over time between groups were carried out using analysis of variance (ANOVA). Correlation coefficients given are Spearman’s. P values are two-sided and 0.05 was considered to indicate statistical significance. Data were analyzed using a commercially available software package (SPSS, Chicago, IL, USA).

**Results**

**Baseline characteristics**

Sixty-three normo-ovulatory women entered the study protocol. In the first study, 11 and 12 subjects were assigned to groups A and B respectively. In the second study, 13, 13 and 14 subjects were allocated to groups C, D and E respectively. With regard to the distribution of age, cycle length and baseline endocrine hormone concentrations showed a significant decrease from the early follicular phase to their highest levels in the mid follicular phase (P < 0.01). Inhibin A and E2 levels increased significantly in the late follicular phase (P < 0.001 and P < 0.001 respectively). In group A, FSH serum concentrations showed a significant decrease from the early to mid follicular phase (P = 0.001), with a subsequent decrease in inhibin B concentrations from the early to late follicular phase (P < 0.05). Groups B, C and D (all starting exogenous FSH in the early follicular phase or at the beginning of the mid follicular phase) all showed an increase in inhibin B levels from the early to mid follicular phase (P < 0.01). Subsequent decrease in inhibin B concentrations from the early to late follicular phase (P < 0.05). Groups B, C and D (all starting exogenous FSH in the early follicular phase or at the beginning of the mid follicular phase) all showed an increase in inhibin B levels from the early to mid follicular phase (P < 0.01). The increase started later with a significant increase from the mid to the late follicular phase (P < 0.01), the increase started later with a significant increase from the mid to the late follicular phase (P < 0.01).
Table 1 Baseline characteristics (median and range) in 63 healthy female normo-ovulatory volunteers participating in the study with various intervention regimes with exogenous FSH.

<table>
<thead>
<tr>
<th>Intervention group</th>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A (n = 11)</td>
<td>B (n = 12)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>28 (25–33)</td>
<td>28 (20–34)</td>
</tr>
<tr>
<td>Cycle length (days)</td>
<td>28 (27–30)</td>
<td>29 (27–30)</td>
</tr>
<tr>
<td>FSH (IU/l)*</td>
<td>5.1 (3.9–6.0)</td>
<td>5.1 (3.8–7.7)</td>
</tr>
<tr>
<td>E2 (pmol/l)*</td>
<td>156 (102–230)</td>
<td>143 (106–259)</td>
</tr>
<tr>
<td>Inhibin A (ng/l)*</td>
<td>5 (2–9)</td>
<td>5 (2–6)</td>
</tr>
<tr>
<td>Inhibin B (ng/l)*</td>
<td>98 (29–221)</td>
<td>154 (68–234)</td>
</tr>
</tbody>
</table>

*All baseline endocrine parameters were assessed on cycle day 3 (pre-intervention cycle for group A and B, intervention cycle for groups C, D and E).

phase (P < 0.05). In all five intervention groups inhibin A and E2 levels increased during the follicular phase, except group A showing a significant increase between early and mid follicular phase levels (inhibin A and E2 levels: P < 0.001 and P < 0.001, P < 0.001 and P < 0.001, and P < 0.05 and P < 0.001 for groups B, C, D and E respectively), and all groups showing a significant increase between mid and late follicular phase levels (P < 0.001 and P < 0.001, P < 0.001 and P < 0.001, P < 0.001 and P < 0.001, and P = 0.001 and P = 0.001, for groups A, B, C, D and E respectively).

In the early follicular phase, group A showed a significant rise in FSH concentrations (P < 0.001), with a subsequent rise in inhibin B concentrations (P < 0.001) compared with the natural cycle. Also group C showed increased FSH (P < 0.001) and inhibin B (P < 0.001) concentrations compared with the natural cycle. In the mid follicular phase serum hormone levels in group A were comparable with the concentrations in the natural cycle. In groups B, C and D, however, inhibin B, inhibin A, E2 and FSH concentrations were all increased compared with the natural cycle (respectively P = 0.01, P < 0.01, P < 0.001 and P < 0.01 for group B; P < 0.05, P < 0.001, P < 0.05 and P < 0.001 for group C and P = 0.001, P < 0.001, P < 0.01 and P < 0.001 for group D). Mid follicular inhibin B levels in group E were comparable with the natural cycle, whereas inhibin A, E2 and FSH levels were increased (P < 0.001, P < 0.05 and P < 0.001 respectively).

No differences were observed comparing the natural cycle and group A in the late follicular phase. The other intervention groups showed late follicular inhibin B levels comparable with the natural cycle, except for group E, which showed a significant rise in inhibin B levels (P < 0.001). These intervention groups all showed a significant rise in late follicular inhibin A levels compared with the natural cycle (P < 0.01, P < 0.001, P < 0.001 and P < 0.001 for groups B, C, D and E respectively). No differences were found in E2 concentrations, except for a slight increase in group B (P < 0.05).

**Follicle growth and serum inhibin concentrations**

In the natural cycle the rise in serum inhibin B levels coincided with a similar increase in the number of small antral follicles with diameters ranging from 5 to 11 mm (Pearson’s correlations between inhibin B and follicles ranging from 5 to 9 mm and from 9 to 11 mm: r = 0.423, P < 0.001 and r = 0.316, P = 0.01 respectively). Inhibin A increased only after a follicle of 15 mm or larger was detected during the late follicular phase (Pearson’s correlations between inhibin A and follicles ranging from 15 to 16 mm and from 17 to 18 mm: r = 0.357, P < 0.05 and r = 0.427, P < 0.01 respectively).

Interventions C, D and E all resulted in a significant increase (P < 0.01) in the number of follicles measuring 10 mm or more. In total, 24 subjects (60%) from groups C, D and E showed multi-follicular growth (defined as >1 follicle measuring >10 mm at the day of hCG administration). In multi-follicular cycles, mid follicular inhibin B levels were significantly elevated compared with mono-follicular cycles (median mid follicular inhibin B 245 ng/l (range 75–830) vs 147 ng/l (range 57–291) for multi- and mono-follicular cycles, P = 0.001). In the late follicular phase median inhibin B, inhibin A and E2 levels were elevated in multi-follicular cycles compared with the mono-follicular cycles (median late follicular inhibin B 230 ng/l (range 50–902) vs 113 ng/l (range 76–298), P < 0.05; inhibin A 75 ng/l (range 14–185) vs 39 ng/l (range 14–57), P < 0.01 and E2 886 pmol/l (range 221–2188) vs 664 pmol/l (range 310–807), P < 0.05 respectively).

Table 2 shows the relation between median early, mid or late follicular phase levels of inhibin B, inhibin A, FSH and E2 with the number of follicles of different size categories in the five intervention cycles. Only the early follicular inhibin B concentration correlated...
slightly with the number of small follicles at the end of the follicular phase. In contrast, in the mid follicular phase inhibin B levels, as well as inhibin A levels, correlated with the number of developing larger follicles. In the late follicular phase a strong correlation was found between inhibin B, inhibin A and E2 levels and the number of larger follicles at the end of the follicular phase.

Discussion

The present study in normo-ovulatory women confirms that inhibin B is indeed mainly produced by small antral follicles and hence inhibin B levels increase during the early to mid follicular phases. Thereafter, inhibin B levels decline during the late follicular phase. Inhibin A is predominantly produced by the pre-ovulatory follicle and serum concentrations are therefore high during the late follicular phase. An increase in FSH stimulation during the early follicular phase induces an increased growth of small antral follicles and hence elevated inhibin B concentrations. If this increase in FSH is long enough to extend the FSH window (the period during which FSH levels are above the threshold for ovarian stimulation (31, 33)), the intervention can result in ongoing multi-follicular growth and hence an increase in both inhibin B and inhibin A. However, if the selection of the single dominant follicle is not affected, serum inhibin B levels return to normal and inhibin A levels remain comparable with serum levels in the natural cycle.

In the natural cycle serum inhibins showed the expected pattern. After the initial rise in FSH a number

Table 2: Pearson’s correlations (r) between median early-, mid- and late-follicular phase levels of inhibin B, inhibin A, FSH and E2 and the number of follicles of different size categories in the late follicular phase of various intervention cycles in 63 normo-ovulatory women.

<table>
<thead>
<tr>
<th>Number of follicles</th>
<th>Number of follicles</th>
<th>Number of follicles</th>
</tr>
</thead>
<tbody>
<tr>
<td>5–10 mm</td>
<td>10–15 mm</td>
<td>15–20 mm</td>
</tr>
<tr>
<td>Inhibin B (ng/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early</td>
<td>0.280*</td>
<td>–0.256*</td>
</tr>
<tr>
<td>Mid</td>
<td>0.293*</td>
<td>0.352**</td>
</tr>
<tr>
<td>Late</td>
<td>0.128</td>
<td>0.536***</td>
</tr>
<tr>
<td>Inhibin A (ng/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early</td>
<td>–0.103</td>
<td>–0.054</td>
</tr>
<tr>
<td>Mid</td>
<td>0.135</td>
<td>0.084</td>
</tr>
<tr>
<td>Late</td>
<td>0.106</td>
<td>0.378**</td>
</tr>
<tr>
<td>FSH (IU/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early</td>
<td>–0.158</td>
<td>0.012</td>
</tr>
<tr>
<td>Mid</td>
<td>–0.044</td>
<td>0.202</td>
</tr>
<tr>
<td>Late</td>
<td>–0.162</td>
<td>0.018</td>
</tr>
<tr>
<td>E2 (pmol/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early</td>
<td>–0.056</td>
<td>–0.099</td>
</tr>
<tr>
<td>Mid</td>
<td>0.162</td>
<td>0.044</td>
</tr>
<tr>
<td>Late</td>
<td>0.086</td>
<td>0.360**</td>
</tr>
</tbody>
</table>

*Day of LH surge (groups A and B): day of hCG (groups C, D and E).
Level of significance: *P < 0.05; **P < 0.01; ***P < 0.001.
of small antral follicles is recruited and subsequently inhibin B is produced. Thereafter, the dominant follicle is selected and smaller follicles from the recruited cohort become atretic. Hence, inhibin B levels decrease (2, 3). Inhibin A and E2 levels increase after the dominant follicle selection (12, 22, 34). Inhibin B serum concentrations in the natural cycle showed a biphasic pattern in the mid to late follicular phase. This pattern correlated highly with the number of follicles measuring up to 11 mm, whereas the number of follicles larger than 11 mm was relatively constant in this phase of the cycle, suggesting that inhibin B mainly originates from follicles up to 11 mm. A similar relationship has been reported recently in menstrual cycles of normo-ovulatory women (35).

In the current study, inhibin B levels were increased in all intervention cycles during which exogenous FSH was administered. Moreover, in those cycles with multifollicular development the highest levels were recorded. When the FSH window is effectively broadened more small follicles will emerge from the recruitable pool (28). Since inhibin B is mainly produced by small antral follicles up to 12 mm in size it might constitute a marker for multiple follicle development (36). In the current study, inhibin B serum concentrations during the early and mid follicular phases were indeed significantly correlated with the number of small developing follicles. Moreover, mid and late follicular phase inhibin B levels were higher in those cycles which resulted in multifollicular development, reflected in significant correlations in mid and late follicular phase inhibin B levels and the number of larger follicles at the end of the follicular phase (the day of the LH surge or the day of hCG administration). Apparently, mid and late follicular phase inhibin B concentrations during ovarian (hyper) stimulation constitute a marker for the number of developing follicles (25, 26).

Prediction of those women who may under- or overrespond to ovarian (hyper) stimulation protocols is of clinical importance. During ovarian stimulation (ovulation induction or ovarian hyperstimulation) it has been shown that the number of follicles measuring 12 mm or more at the day of hCG administration is strongly correlated with the incidence of high order multiple pregnancies (37, 38). Similarly, E2 serum concentrations are strongly correlated with adverse outcome (38). Since mid follicular inhibin B serum concentrations were correlated both with the number of follicles measuring 10 mm or more as well as with multifollicular development, inhibin B might also constitute a predictor of multiple gestation during ovarian hyperstimulation. Ideally, such a predictor should be sufficiently accurate and distinct in time from the moment that stimulation protocols are commenced (39). Consequently, based on early follicular phase inhibin B serum levels, treatment might be optimized since women at risk for ovarian hyperstimulation syndrome and multiple pregnancies might be more easily identified prior to treatment. Unfortunately, in the current study as in others, the basal inhibin B serum levels did not correlate with the final pre-ovulatory number of follicles (18, 19, 39, 40). Moreover, early basal as well as stimulated inhibin B levels seem to reflect the potential follicular development of the ovary, but are not significantly associated with the final oocyte number which is mainly determined by the antral follicle count and the basal FSH serum concentration (39). Therefore, inhibin B constitutes a poor marker in the risk assessment of women who might over-respond to treatment.

In conclusion, the present data extend our understanding of the relationship between follicle dynamics, serum inhibins and FSH levels during multiple dominant follicle development resulting from ovarian hyperstimulation with exogenous FSH. However, although mid follicular inhibin B does correlate with the number of developing follicles, it does not facilitate the identification of women at risk for multiple follicle development.

References

Inhibins and ovarian stimulation

401

Inhibin A and inhibin B are synthesized by granulosa and theca cells of the ovarian follicle during the folliculogenesis process. They act as paracrine factors to regulate the growth and maturation of the follicle. Inhibin A is composed of a combination of inhibin α and inhibin βA chains, whereas inhibin B is composed of inhibin α and inhibin βB chains. These proteins affect the secretion of FSH and LH by the pituitary gland, thus playing a crucial role in the regulation of follicular development, ovulation, and implantation in the uterus.


Siepier L, Hop WC & Fauser BC. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. *Journal of Clinical Endocrinology and Metabolism* 1998 83 1292–1298.


van Santbrink EJ, Hop WC, van Derss T, de Jong FH & Fauser BC. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. *Fertility and Sterility* 1998 64 37–43.


Yong PY, Baird DT, Thong KJ, McNeilly AS & Anderson RA. Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation. *Human Reproduction* 2003 18 35–44.